The rise of weight-loss drugs like Ozempic has not only changed the way individuals approach their health and weight management but is also having a significant impact on the fashion industry. As the popularity of weight-loss medications increases, the plus-size fashion market is experiencing notable shifts. This shift has experts, designers and consumers wondering if the so-called "ultra-thinness" ideal, which was a staple of the '90s and '00s, is making a return and whether that spells trouble for the size-inclusive fashion market, business models, product lines, and the body positivity movement.
Ozempic is a prescription medication developed by leading Danish pharmaceutical company, Novo Nordisk. The drug works by mimicking a hormone that regulates appetite and digestion which in turn leads to reduced hunger and calorie intake. This combined with its ability to slow down digestion helps users reduce their body weight.
It was designed to treat and manage type 2 diabetes, but has found popularity because of its weight loss effects. Several celebrities are known to have used the drug. A representative for Novo Nordisk told that the company was "committed to the responsible use of our medicines.
" "Ozempic is not approved for chronic weight management," the representative said. Of the 8,800 looks presented across 230 shows and presentations during this year's Autumn-Winter fashion season, just 0.8 percent were plus-size (US 14+) and 3.
7 percent were mid-size (US 6-12). An overw.
